

RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE

This author's accepted manuscript may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

The full details of the published version of the article are as follows:

TITLE: Approach to canine paroxysmal dyskinesias

AUTHORS: Christoforos Posporis, Sophie Wyatt, Annette Wessmann

JOURNAL: Companion Animal

PUBLISHER: Wiley

PUBLICATION DATE: May 2018

DOI: <https://doi.org/10.12968/coan.2018.23.5.276>

1 **Approach to Canine Paroxysmal Dyskinesias**

2

3 C. Posporis¹ and S. Wyatt², A. Wessmann¹

4 ¹Pride Veterinary Centre, Derby, UK, ²Royal Veterinary College, Hatfield, UK.

5

6 Corresponding author: Annette Wessmann

7 Address: Pride Veterinary Centre, Riverside Road, Derby, DE24 8HX, UK.

8 E-mail address: annette.wessmann@scarsdalevets.com

9

10 Keywords: Movement Disorder; Seizure; Canine; Dystonia; Hypertonicity; Involuntary
11 movement.

12 **Introduction**

13 The term ‘paroxysmal dyskinesia’ (PD) describes a manifestation of abnormal involuntary
14 muscle contraction which by definition is episodic in nature and self-limiting (Lowrie &
15 Garosi 2017). There have been numerous published articles concerning PDs over recent
16 years and the earliest report in veterinary literature dates back to 1942 concerning
17 ‘Scottie Cramp’ in Scottish terriers (Klarenbeek 1942). Despite this, PDs remain a
18 poorly understood and frequently under-recognised condition in veterinary patients
19 (Richter et al. 2015; Strain 2016). Some useful terminology when considering this
20 subject is included in table one. The purpose of this article is to review the basic
21 classification and principles of recognition and diagnosis of PDs. This article will also
22 introduce some of the breed-specific PDs, as well as the treatment/management options
23 available and expected outcomes.

24
25 PDs encompass a number of clinical signs with specific terminology, as detailed in table two
26 (Kent 2012). Dystonia tends to be the most common clinical sign which is characterised
27 by sustained and often repetitive muscle contraction in one or several limbs (Lowrie &
28 Garosi 2017). This results in abnormal postures or twisting and tremor-like movements
29 (Richter et al. 2015), which can initially appear confusing and alarming to owners and
30 veterinary surgeons alike. Affected animals may collapse and become recumbent as a
31 result of their dystonic movements, but they will frequently remain standing and
32 responsive to their external environment (Platt 2016). For example, affected animals
33 may continue to attempt engagement in play or show interest in food (figure one). PDs
34 can last from seconds to hours, often with an abrupt beginning and end (Lowrie &
35 Garosi 2017). They occur in the conscious animal and neurological examination is
36 typically normal between episodes. PDs may be triggered by stress, exercise or

37 excitement. There are also reports of drug-induced PDs (Kube et al. 2006; Mitek et al.
38 2013). The remainder of this article will largely concern primary PDs.
39
40 Current understanding suggests PDs are most likely the result of transient abnormal activity
41 within deep collections of grey matter within the cerebral hemispheres (Lowrie &
42 Garosi 2017); these areas are otherwise known as basal nuclei and are important in
43 initiation and control of motor activity. Findings which help to support this theory
44 include identification of lesions within the basal nuclei of patients with PDs (Bhatia &
45 Marsden 1994; Gernert et al. 2000) and hyperactivity within basal nuclei during PD
46 episodes, diagnosed using single photon emission computed tomography (Berti et al.
47 2011). Despite this evidence, the underlying cause of PDs remains controversial and ion
48 channelopathies, as well as functional imbalances of neurotransmitters within the brain,
49 are also implicated in their pathogenesis (Lee 1979). PDs have been linked to epilepsy
50 on a pathophysiological basis (Crompton & Berkovic 2009) although PDs and epilepsy
51 are now regarded as two very separate disorders.

52

53 *Classification*

54 Numerous clinical classification systems have been suggested in recent years for PDs. One of
55 the more widely known classification systems adapted from human literature identifies
56 three main groups of PDs: paroxysmal kinesigenic (action-induced) dyskinesia (PKD),
57 paroxysmal non-kinesigenic dyskinesia (PNKD) and paroxysmal exertion-induced
58 dyskinesia (PED) (Waln & Jankovic 2015). The details and differentiating features of
59 each classification group are detailed in table three. Although it is useful to have an
60 awareness of the characteristic features of each of these classification groups, the
61 majority of cases in veterinary medicine are consistent with PNKD. Therefore, the direct

62 clinical relevance of this human classification is currently unclear. An additional sub-
63 classification for veterinary patients was recently proposed based on suspected aetiology
64 of PDs, which may have more relevant clinical application (Lowrie & Garosi 2017).

65 (1) Genetic causes – A genetic mutation of the brevican gene (*BCAN*) is implicated in
66 episodic falling syndrome in Cavalier King Charles Spaniels (Gill et al. 2012). A
67 mutation has also been identified in the *PIGN* gene which is linked to a PD in Soft-
68 coated Wheaten terriers (Kolicheski et al. 2017).

69 (2) Dietary causes – Paroxysmal gluten sensitive dyskinesia (PGSD) is a type of PNKD
70 well characterised in Border terriers (Black et al. 2014; Lowrie et al. 2018). The
71 disorder shows a variable response to a gluten free diet with complete resolution of
72 clinical signs in some cases (Lowrie et al. 2015).

73 (3) Secondary causes – Previous reports exist of PDs which occurred as a result of
74 phenobarbital administration (Kube et al. 2006), or following the use of propofol
75 (Mitek et al. 2013).

76 (4) Presumed genetic/ unidentified causes – An autosomal recessive mode of inheritance
77 is presumed in several breed-related PDs, which have characteristic phenotypic
78 features. These include ‘Scottie Cramp’ in Scottish terriers, as well as a familial
79 occurrence of PDs reported in the Chinook breed of dog (Lowrie & Garosi 2016;
80 Packer et al. 2010; Urkasemsin & Olby 2015). As of yet, no definitive genetic cause
81 has been identified in these breeds, which can be directly linked to PDs.

82

83 *Diagnosis*

84 Diagnosis of PDs is often speculative and based on observation and assessment of key
85 features of abnormal events. Due to the intrinsic nature of PDs, which are episodic and
86 sometimes situation-specific, they are rarely observed on presentation to a veterinary

87 surgeon. Video recording and documentation of abnormal events has aided diagnosis in
88 recent years with increased accessibility to smart-phone technology to record abnormal
89 events at home. The marked heterogeneity and overlap with other transient disorders in
90 terms of clinical features, can make accurate identification and recognition of PDs
91 challenging (Lowrie & Garosi 2017). In addition, the co-occurrence of PDs with
92 conditions such as epilepsy as seen in the Chinook dogs can further add to the diagnostic
93 challenge associated with PDs (Packer et al. 2010).

94

95 Differential diagnosis for PDs can include seizure episodes, neuromuscular disease,
96 idiopathic tremors, tetanic spasms, narcoleptic/cataplexic disorders, vestibular attacks,
97 syncopal episodes, acute pain syndrome, and paroxysmal behavioural episodes (Richter
98 et al. 2015). This list is by no means exhaustive and all of the above should be
99 considered when making a diagnosis of PD. Table four identifies some of the main
100 differentiating features between PDs and seizure episodes. One of the main challenges is
101 the differentiation of PDs from simple focal seizures, which like PDs, are not associated
102 with impaired consciousness. In contrast, simple focal seizures are often associated with
103 obvious lateralisation of clinical signs due to unilateral cerebral involvement, while PDs
104 often result in more generalised signs involving all limbs/both sides of the body.
105 Although it is important to be aware of the limitations and potential inaccuracies of
106 diagnosing by observation alone, it is a useful first step in identifying PDs.

107

108 The availability of advanced imaging along with time-consuming or invasive diagnostics
109 (e.g. cerebrospinal fluid analysis and electrodiagnostics) is often limited in general
110 practice, yet this does not preclude the possibility of making an accurate diagnosis of
111 PDs (Lowrie & Garosi 2017). Advanced diagnostics are frequently of limited value

112 when making a diagnosis of PDs and often ‘unremarkable’. Accurate clinical reasoning
113 and judgement is vital when considering a case with possible PDs. Definitive diagnostic
114 tests exist for very few PDs but serological testing in Border terriers for example, or
115 genetic testing in Cavalier King Charles Spaniels and Soft-coated Wheaten terriers is
116 available for breed-specific conditions and can easily be performed in a general practice
117 setting. It is essential to obtain a thorough clinical history, full physical and neurological
118 examination, in addition to obtaining a minimum database (routine blood work and
119 urinalysis) as part of the diagnostic workup.

120

121 Breed-specific PDs in dogs (table five)

122 *A. Paroxysmal dyskinesia of Scottish terriers (Scottie Cramp)*

123 This episodic hyperkinetic syndrome described in this breed is now classified as a PNKD
124 (Klarenbeek 1942; Lowrie & Garosi 2017). Clinical signs become evident from one
125 month to seven years of age and females are overrepresented. Clinical signs consist of
126 hypertonicity, arching of the lumbar spine, a stiff gait, flexion of the pelvic limbs,
127 abduction of the thoracic limbs, dystonic postures (pillar-like stance, curling into a
128 ball), skipping steps, and difficulty/inability to walk (Meyers 1970; Urkasemsin &
129 Olby 2015). An autosomal-recessive inheritance pattern is presumed (Meyers 1970)
130 and a defect in serotonin metabolism has been proposed as a possible cause of these
131 episodes but the exact pathophysiological mechanism remains unknown (Meyers &
132 Schab 1974; Peters & Meyers 1977). This is a non-progressive disease and severity
133 can decrease with time. Avoidance of precipitating factors, such as excitement or
134 stress, can help to reduce the frequency of episodes. Diazepam or acepromazine
135 maleate can be used, but fluoxetine appears to be more effective in reducing the
136 frequency and duration of the episodes (Geiger & Klopp 2009; Urkasemsin & Olby

137 2015).

138

139 *B. Paroxysmal gluten-sensitive dyskinesia (PGSD) of Border terriers (BT)*

140 PGSD is another term for a multisystem disorder previously known as canine epileptoid
141 cramping syndrome (CECS) in BTs. An association between gluten sensitivity and
142 this characteristic PD was demonstrated in BTs (Lowrie et al. 2018; Lowrie et al.
143 2015). Age of onset is six weeks to nine years (Black et al. 2014; Lowrie et al. 2018;
144 Stassen et al. 2017). Dystonia of the limbs/ head/ neck, tremors, ataxia, difficulty
145 walking, and inability to maintain a standing position are common associated findings
146 and are often accompanied by borborygmi (Black et al. 2014; Lowrie et al. 2018;
147 Lowrie & Garosi 2017; Lowrie et al. 2015; Urkasemsin & Olby 2015). Signs
148 preceding the event include attention seeking, vomiting, and eating grass (Black et al.
149 2014). Concurrent dermatological and gastrointestinal disease is possible as seen in
150 people with gluten sensitivity (Black et al. 2014; Hadjivassiliou et al. 2003; Lowrie et
151 al. 2018). No genetic mutation could be identified in a cohort of 110 dogs indicating a
152 complex mode of inheritance (Stassen et al. 2017). A link between dietary exclusion
153 of gluten and resolution of clinical signs was shown (Lowrie et al. 2015). Serological
154 testing for anti-transglutaminase-2 and anti-gliadin antibodies in addition to the
155 clinical signs can aid diagnosis. However, these serological markers are not exclusive
156 to PGSD (Lowrie et al. 2018). Institution of a strictly gluten-free diet can serve as a
157 diagnostic and therapeutic tool (Lowrie et al. 2015; Lowrie et al. 2016). Possible
158 PGSD has also been reported in a Yorkshire terrier (Park et al. 2014).

159

160 *C. Episodic falling syndrome of Cavalier King Charles Spaniels (CKCS)*

161 This familial PD is also known under the term ‘episodic hypertonicity of Cavalier King

162 Charles Spaniels' (Garosi et al 2002). There is currently disagreement in veterinary
163 literature about whether this is a non-kinesigenic or exertion-induced PD (Forman et
164 al. 2012; Lowrie & Garosi 2017). Age of onset is three months to four years. Ataxic
165 pelvic limb gait, abduction of the limbs, progressive muscular hypertonicity, dystonic
166 postures (arching of the spine, 'deer-stalking' or 'praying' posture), 'bunny hopping'
167 and collapse are common associated clinical signs (Forman et al. 2012; Gill et al.
168 2012; Herrtage & Palmer 1983). An autosomal recessive mode of inheritance is
169 suspected with around 13% of CKCS carrying the causative genetic mutation
170 (Forman et al. 2012; Gill et al. 2012). A deletion involving the *BCAN* gene, which
171 encodes an aggregating extracellular matrix proteoglycan has been demonstrated.
172 DNA testing is available for diagnostic purposes but long-term may also be useful in
173 the elimination of carrier dogs from breeding programs. Episodic hypertonicity can be
174 a self-limiting disease in CKCS. Clonazepam can result in improvement of clinical
175 signs although tolerance can occur with long-term therapy and acetazolamide
176 represents an alternative therapeutic option (Forman et al. 2012; Garosi et al. 2002;
177 Gill et al. 2012).

178

179 *D. Paroxysmal dyskinesia of Soft-coated Wheaten terriers (SCWT)*

180 Episodic dystonic movements and postures are reported in this breed as part of a familial PD.
181 Age of onset is typically between eight months and three years (Kolicheski et al.
182 2017; O'Brien et al 2015). Episodes are characterised by rapid flexion and extension
183 of pelvic limbs with truncal dystonia and progressive involvement of thoracic limbs in
184 severe cases (Kolicheski et al. 2017). An autosomal recessive trait of inheritance was
185 proposed and a mutation in the gene *PIGN* was demonstrated. The diagnosis can be
186 confirmed by DNA testing. Thus far, there is no proven benefit to treatment with

187 benzodiazepines, antiepileptic drugs and muscle relaxants. Clinical signs may be
188 progressive over time (Kolicheski et al. 2017; O'Brien et. al 2015; Shelton 2004) but
189 medical therapy with acetazolamide has been shown to be effective with some dogs
190 achieving complete resolution of the dyskinesia (O'Brien et. al 2015).

191

192 *E. Paroxysmal dyskinesia of Labrador retrievers*

193 Episodes of dystonic involuntary movements and postures, resembling typical clinical
194 features of PD, are occasionally reported in this breed. Age of onset is from nine
195 months to ten years eight months and the majority of affected dogs are males. No
196 genetic associations were investigated yet and the pathogenesis remains unknown.
197 There is no specific treatment for PDs in this breed but a natural reduction in episode
198 frequency was reported in the majority of dogs and spontaneous remission is possible
199 (Lowrie & Garosi 2016).

200

201 *G. Paroxysmal dyskinesia of Jack Russell terriers (JRT)*

202 The natural history of PDs in JRTs was recently described. Age of onset was from one to
203 eight years. Extremes of temperature preceded the episodes in 83% of dogs. Disease
204 severity decreased over time in 57% of dogs and late spontaneous remission was
205 achieved in 22% of dogs. The mode of inheritance and pathogenesis remain unknown.
206 There is no specific treatment for this PD in JRTs (Lowrie & Garosi 2016).

207

208 *H. Paroxysmal dyskinesia of Chinooks*

209 A familial PD has been reported in this breed. Most dogs develop signs within their first three
210 years of life. Affected dogs are unable to stand or walk during the episodes. Head
211 tremors, flexion of one or more limbs, dystonia, repetitive limb contractions, and

212 collapse were reported. An autosomal recessive or polygenic pattern of inheritance is
213 suspected based on pedigree analysis. Interestingly, the same breed lines, which
214 suffered with PDs were found to suffer from epilepsy, but these two conditions appear
215 to coexist in some dogs. There is no known treatment (Packer et al. 2010).

216

217 *I. Sporadic reports of paroxysmal dyskinesia in other breeds*

218 Typical paroxysmal dyskinesic events were reported in several other breeds including Wire-
219 haired terrier, Norwich terrier, Dalmatians, West Highland White terriers, Cairn
220 terriers, Norwich terriers and Bichon Frise (De Risio & Freeman 2015; Penderis &
221 Franklin 2001; Urkasemsin & Olby 2015; Woods 1977). Episodic hypertonicity was
222 also seen in Springer Spaniels and Boxer puppies (Ramsey et al. 1999; Shelton 2004).
223 A 12-week-old female Golden Retriever with suspected PD was treated successfully
224 with acetazolamide (Royaux et al. 2015). A phenobarbital-responsive PD was
225 reported in a German shorthaired pointer (GSHP) (Harcourt-Brown 2008). In a recent
226 publication, anecdotal evidence of another GSHP with similar signs that achieved full
227 remission after phenobarbital therapy was presented (Lowrie & Garosi 2017).

228

229 **Closing Comments**

230 PDs comprise a heterogeneous group of disorders with a high degree of phenotypic
231 variability. Video footage and documentation of abnormal episodes can be extremely
232 useful as a first step in identification of PDs. Accurate clinical reasoning and
233 judgement is vital when considering a case with possible PDs and differentiation from
234 other paroxysmal disorders, for example seizure episodes, can be challenging.
235 Although there are several breed-related PDs which are well characterised, PDs may
236 occur in any breed and they remain a poorly understood and frequently under-

237 recognised condition in veterinary patients. A genetic and/or pathophysiological
238 classification would not only facilitate the diagnosis of PDs, but it may also support
239 the development of new therapeutic approaches.

240 **References**

241

242 Berti, V., Pupi, A. & Mosconi, L. (2011) PET/CT in diagnosis of movement disorders.
243 *Annals of the New York Academy of Sciences* 1228, 93–108

244

245 Bhatia, K.P. & Marsden, C.D. (1994) The behavioral and motor consequences of focal
246 lesions of the basal ganglia in man. *Brain* 117, 859–876

247

248 Black, V., Garosi, L., Lowrie, M., et al. (2014) Phenotypic characterisation of canine
249 epileptoid cramping syndrome in the Border terrier. *Journal of Small Animal Practice*
250 55, 102–107

251

252 Crompton, D.E. & Berkovic, S.F. (2009) The borderland of epilepsy: clinical and molecular
253 features of phenomena that mimic epileptic seizures. *The Lancet Neurology* 8, 370–381

254

255 De Risio, L. & Freeman, J. (2015) Epileptoid cramping syndrome in the Norwich terrier:
256 clinical characterisation and prevalence in the UK. *Proceedings 28th ESVN-ECVN*
257 *congress*

258

259 Forman, O.P., Penderis, J., Hartley, C., et al. (2012) Parallel mapping and simultaneous
260 sequencing reveals deletions in BCAN and FAM83H associated with discrete inherited
261 disorders in a domestic dog breed. *PloS Genetics* 8(1),e1002462

262

263 Garosi, L.S., Platt, S.R. & Shelton, G.D. (2002) Hypertonicity in Cavalier King Charles
264 spaniels. *Journal of Veterinary Internal Medicine* 16, 330

265

266 Geiger, K.M. & Klopp, L.S. (2009) Use of a selective serotonin reuptake inhibitor for
267 treatment of episodes of hypertonia and kyphosis in a young adult Scottish terrier.
268 *Journal of the American Veterinary Medical Association*. 235, 168-171

269

270 Gernert, M., Hamann, M., Bennay, M., et al. (2000) Deficit of striatal parvalbumin-reactive
271 GABAergic interneurons and decreased basal ganglia output in a genetic rodent model
272 of idiopathic paroxysmal dystonia. *The Journal of Neuroscience* 20, 7052–7058

273

274 Gill, J.L., Tsai, K., Krey, C., et al. (2012) A canine BCAN microdeletion associated with
275 episodic falling syndrome. *Neurobiology of Disease* 45, 130–136

276

277 Hadjivassiliou, M., Grünwald, R. & Sharrack, B. (2003). Gluten ataxia in perspective:
278 epidemiology, genetic susceptibility and clinical characteristics. *Brain* 123, 685-891

279

280 Harcourt-Brown, T. (2008) Anticonvulsant responsive, episodic movement disorder in a
281 German shorthaired pointer. *Journal of Small Animal Practice* 49, 405-407

282

283 Herrtage, M.E. & Palmer A.C. (1983) Episodic falling in the cavalier King Charles spaniel.
284 *Veterinary Record* 112, 458-459

285

286 Kent, M. (2012) Acute tremors and involuntary movements. In: *Small Animal Neurological*
287 *Emergencies*. Eds S. R. Platt and L. Garosi. Manson Publishing Ltd, London, UK. pp
288 250–252

289
290 Klarenbeek, A. (1942) An intermittently appearing disturbance in the regulation of the leg
291 tonus observed in Scottish terriers. *Tijdschr Diergeneesk* 69, 14–21
292
293 Kolicheski, A.L., Johnson, G., Mhlanga-Mutangadura, T., et al. (2017) A homozygous PIGN
294 missense mutation in Soft-coated Wheaten terriers with a canine paroxysmal dyskinesia.
295 *Neurogenetics* 18, 39–47
296
297 Kube, S.A., Vernau, K.M. & LeCouteur, R.A. (2006) Dyskinesia associated with oral
298 phenobarbital administration in a dog. *Journal of Veterinary Internal Medicine* 20,
299 1238–1240
300
301 Lee, A.S. (1979) Treatment of drug-induced dystonic reactions. *Journal of the American*
302 *College of Emergency Physicians* 8, 453–457
303
304 Lowrie, M., Garden, O.A., Hadjivassiliou, M., et al. (2018) Characterization of paroxysmal
305 gluten-sensitive dyskinesia in Border terriers using serological markers. *Journal of*
306 *Veterinary Internal Medicine*. doi: 10.1111/jvim.15038
307
308 Lowrie, M., Garden, O.A., Hadjivassiliou, M., et al. (2015) The clinical and serological effect
309 of a gluten-free diet in Border terriers with epileptoid cramping syndrome. *Journal of*
310 *Veterinary Internal Medicine* 29, 1564–1568
311
312 Lowrie, M. & Garosi, L. (2017) Classification of involuntary movements in dogs :
313 Paroxysmal dyskinesias. *The Veterinary Journal* 220, 65–71
314
315 Lowrie, M. & Garosi, L. (2016) Natural history of canine paroxysmal movement disorders in
316 Labrador retrievers and Jack Russell terriers. *The Veterinary Journal* 213, 33-37
317
318 Lowrie, M., Hadjivassiliou, M., Sanders, D.S., et al. (2016) A presumptive case of gluten
319 sensitivity in a border terrier: a multisystem disorder? *Veterinary Record* 179, 573
320
321 Mitek, A.E., Clark-Price, S.C. & Boesch, J.M. (2013) Severe propofol-associated dystonia in
322 a dog. *Canadian Veterinary Journal* 54(5), 471–474
323
324 Meyers, K.M., Padgett, G.A & Dickson, W.M. (1970) The genetic basis of a kinetic disorder
325 of Scottish terrier dogs. *Journal of Heredity* 61, 189-192
326
327 Meyers, K.M. & Schab B. (1974) The relationship of serotonin to a motor disorder of
328 Scottish terrier dogs. *Life Sciences* 14, 1895-1906
329
330 O'Brien, D., Kolicheski, A., Packer, R., et al. (2015) Paroxysmal non-kinesogenic dyskinesia
331 in Soft-coated Wheaten terriers associated with a missense mutation in PIGN and
332 responds to acetazolamide therapy. *Journal of Veterinary Internal Medicine*.
333 doi:10.1111/jvim.13002; ACVIM Forum Research Reports Program.
334
335 Packer, R.A. Patterson, E.E., Taylor, J.F., et al. (2010) Characterization and mode of
336 inheritance of a paroxysmal dyskinesia in Chinook dogs. *Journal of Veterinary Internal*
337 *Medicine* 24, 1305–1313
338

339 Park, H.J., Seo, D.K, Song, K.H., et al. (2014) Paroxysmal dyskinesia suspected as canine
340 epileptoid cramping syndrome in a young Yorkshire terrier dog. *Journal of Veterinary*
341 *Medical Science* 76, 1129-1132
342

343 Penderis, J. & Franklin, R.J. (2001) Dyskinesia in an adult bichon frise. *Journal of Small*
344 *Animal Practice* 42, 24-25
345

346 Peters, R.I.Jr. & Meyers, K.M. (1977) Precursor regulation of serotonergic neuronal function
347 in Scottish terrier dogs. *Journal of Neurochemistry* 29, 753-755
348

349 Platt, S. (2016) Involuntary movements and paroxysmal disorders. In: Practical Guide to
350 Canine and Feline neurology. Eds C. W. Dewey and R. C. da Costa. Wiley Blackwell,
351 Iowa, USA. pp 270–271
352

353 Ramsey, I.K., Chandler, K.E. & Franklin, R.J.M. (1999) A movement disorder in Boxer
354 pups. *Veterinary Record* 144, 179
355

356 Richter, A., Hamann, M., Wissel, J., et al. (2015) Dystonia and paroxysmal dyskinesias:
357 under-recognized movement disorders in domestic animals? A comparison with human
358 dystonia/paroxysmal dyskinesias. *Frontiers in Veterinary Science* 2, 1–14
359

360 Royaux, E., Bhatti, S., Harvey, R., et al. (2015) Acetazolamide-responsive paroxysmal
361 dyskinesia in a 12-week-old female Golden Retriever dog. *Veterinary Quarterly* 36, 45-
362 49
363

364 Shelton, G.D. (2004) Muscle pain, cramps and hypertonicity. *Veterinary Clinics of North*
365 *America Small Animal Practice* 34, 1483-1496
366

367 Stassen, Q.E.M., Koskinen, L.L.E., van Steenbeek, F.G. et al. (2017). Paroxysmal dyskinesia
368 in Border terriers: Clinical, epidemiological, and genetic investigations. *Journal of*
369 *Veterinary Internal Medicine* 31, 1123-1131
370

371 Strain, G.M. (2016) A framework for movement disorders in canine neurology. *The*
372 *Veterinary Journal* 214, 122–123
373

374 Urkasemsin, G. & Olby, N.J. (2015) Clinical characteristics of Scottie Cramp in 31 cases.
375 *Journal of Small Animal Practice* 56, 276–280
376

377 Waln, O. & Jankovic, J. (2015) Paroxysmal movement disorders. *Neurologic Clinics* 33,
378 137–152
379

380 Woods, C.B. (1977) Hyperkinetic episodes in two Dalmatian dogs. *Journal of American*
381 *Animal Hospital Association* 13, 255-257
382
383
384

385 **Table one – Useful terms when considering the subject of PDs**

Paroxysmal	A sudden occurrence or intensification of clinical signs which is episodic in nature
Dyskinesia	Impairment or abnormal voluntary movement
Movement Disorder	A condition affecting the ability of an individual to initiate or control movement, often resulting in abnormal voluntary/involuntary movements
Paroxysmal kinesigenic dyskinesia (PKD)	A form of PDs precipitated by sudden movement
Paroxysmal non-kinesigenic dyskinesia (PNKD)	A form of PDs associated with stress or excitement, but not precipitated by movement
Paroxysmal exertion-induced dyskinesia (PED)	A form of PDs associated with heavy exercise

386

387 **Table two – Clinical signs associated with PDs and their definitions**

Dystonia	Sustained involuntary muscle contraction causing abnormal postures
Athetosis	Prolonged, slow, involuntary contraction involving musculature of the trunk causing writhing and contortion of the body
Chorea	Unsustained involuntary muscle contraction causing abrupt movements
Choreoathetosis	Involuntary muscle contraction involving a combination of the athetosis and chorea
Ballism	Abrupt contraction of limb musculature causing flailing movements of the limbs, often unilateral

388

389

390 **Table three – Summary of the key features associated with the three main categories of**
 391 **PDs based on a human classification system**
 392

Feature	PKD	PNKD	PED
Trigger	Sudden movement	Stress, caffeine, alcohol	Heavy exercise
Age of onset	Childhood/adolescent	Childhood/adolescent	Variable
Duration	< 5 minutes	2 – 4 minutes	5 minutes – 2 hours
Frequency	Variable – multiple attacks per day, may improve with age	Variable - several per week to several in a lifetime	Dependant on exercise
Treatment	Anticonvulsants including carbamazepine	Trigger avoidance, benzodiazepines	Trigger avoidance, ketogenic diet, gabapentin

PKD, paroxysmal kinesigenic dyskinesia; PNKD, paroxysmal non-kinesigenic dyskinesia; PED, paroxysmal exertion-induced dyskinesia.

393 **Table four – Differentiating clinical characteristics of PDs and seizure episodes**

Paroxysmal Dyskinesia	Seizure Episode
No impairment of consciousness	Reduced/ absent conscious responses
No autonomic signs	Autonomic signs may be present, e.g. hypersalivation, urination/defecation
Usually abrupt onset	Possible prodromal behavioural abnormalities
No abnormal post-ictal behaviours	Post-ictal behavioural changes may be present
Variable duration (seconds to hours)	Usually of short duration (<5 minutes)
Unremarkable neurological examination in between episodes	Possible persistent/ transient inter-ictal neurological abnormalities

395 **Table five – Breed specific PDs**

Breed specific PD	Reported age of onset	Suspected mode of inheritance	Genetic mutation	DNA test	Treatment	Prognosis
Scottie Cramp	One month to seven years	Autosomal recessive	Currently unknown	No	Fluoxetine Acepromazine Diazepam	Fair prognosis: non-progressive disease, severity can decrease with time
PGSD/CECS of Border terriers	Six weeks to nine years	Currently unknown	Currently unknown	No [§]	Gluten-free diet	Good prognosis: variable but generally good response to gluten-free diet
Episodic falling syndrome of CKCS	Three months to four years	Autosomal recessive	BCAN gene	Yes [¥]	Clonazepam, acetazolamide	Good prognosis: it can be a self-limiting disease
PD of Soft-coated Wheaten terrier	Median: two years	Autosomal recessive	PIGN gene	Yes	Acetazolamide	Guarded prognosis without treatment: generally progressive disease; Fair prognosis with treatment: improvement or resolution of signs is possible.
PD of Labrador retrievers	Nine months to ten years eight months	Currently unknown	Currently unknown	No	No known treatment*	Good prognosis: reduction in episode frequency can be seen in the majority of dogs and spontaneous remission is possible
PD of JRT	One to eight years	Currently unknown	Currently unknown	No	No known treatment*	Fair prognosis: Disease severity can decrease over time in some dogs and late spontaneous remission is possible
PD of Chinooks	Two months to five years	Autosomal recessive or polygenic trait	Currently unknown	No	No known treatment*	Unknown

396 * Medications such as clonazepam, acetazolamide or fluoxetine can be trialled for PD if episode frequency is not
397 satisfactory.

398 § Serological testing is available (anti-transglutaminase-2 IgA and anti-gliadin IgG antibodies).

399 ¥ A number of homozygous dogs remain asymptomatic.

401 Figure one – a) dystonia, choreoathetosis and ballism, exhibited by an 18 month-old male
402 neutered Labrador retriever; b) dystonia and choreoathetosis resulting in collapse and
403 recumbency in a 4 year-old male entire Yorkshire terrier.



404